Table 3. Summary of genes identified at QTLs and potential functional variants.
Shown are the phenotype measured, the chromosome (chr.), the start and stop coordinates of the QTL, gene symbol and description, whether the gene is the only one at a QTL with candidate variants, whether a variant alters an amino acid and, if so, the residue changed and the potential consequences.
| Measure | Chr. | QTL location (Mb) |
Gene | Gene description | Only gene with candidate variants in QTL |
Amino acid change with potential effect |
Location of the residue, potential effect |
|---|---|---|---|---|---|---|---|
|
Mean response
latency |
2 | 80.23– 84.83 |
Ctnnd2 | Catenin δ2 | + | None | − |
| Femur neck width | 1 | 156.27– 160.9 |
Fchsd2 | FCH and double SH3 domains protein 2 | + | None | − |
|
Distal femur total
density |
2 | 152.74– 157.22 |
Kcnab1 | Voltage-gated potassium channel subunit β1 |
+ | None | − |
|
Femoral neck
total density |
5 | 4.03– 8.22 |
Eya1 | Eyes absent homolog 1 | + | None | − |
|
Femur midshaft
cortical density |
6 | 38.24– 41.52 |
Lpin1 | Phosphatidate phosphatase LPIN1 | + | None | − |
|
Femur midshaft
total area |
2 | 43.96– 48.57 |
Ndufs4 | NADH dehydrogenase (ubiquinone) iron- sulfur protein 4, mitochondrial |
+ | None | − |
|
Femur work to
failure |
8 | 21.57– 26.17 |
Dpy19l1 | Protein dpy-19 homolog 1 | + | None | − |
|
Lumbar
trabecular area |
20 | 21.1– 25.75 |
F1LW02_RAT | Uncharacterized protein | + | None | − |
| Heart weight | 1 | 202.15– 206.63 |
Shank2 | SH3 and multiple ankyrin repeat domains protein 2 |
+ | None | − |
|
Area under
glycemia curve over baseline |
2 | 80.5– 85.11 |
Ctnnd2 | Catenin δ2 | + | None | − |
|
Hemoglobin
concentration |
12 | 1.62– 5.77 |
Insr | Insulin receptor subunit α, insulin receptor subunit β |
+ | None | − |
|
Mean platelet
mass |
1 | 193.98– 197.88 |
Dock1 | Dedicator of cytokinesis protein 1 | + | None | − |
|
Mean platelet
mass |
9 | 52.53– 88.11 |
ErbB4 | Receptor tyrosine protein kinase erbB– 4ERBB4 intracellular domain |
+ | None | − |
| Platelet clumps | 8 | 100.57– 104.81 |
Clstn2 | Calsyntenin-2 | + | None | − |
| Platelet count | 11 | 14.47– 18.54 |
Hspa8 | Heat shock 70-kDa protein 8 | + | None | − |
|
Absolute
CD25+CD4+ cells |
19 | 50.71– 54.96 |
Galnt2 | Polypeptide N- acetylgalactosaminyltransferase 2 |
+ | None | − |
|
Absolute CD8+ T
cells |
20 | 1.00– 8.90 |
RT1-Db2 | RT1 class II, locus Db2 | + | None | − |
|
Proportion of B
cells in white blood cells |
10 | 27.1– 31.59 |
D3ZTU5_RAT | Uncharacterized protein | + | None | − |
|
Proportion of B
cells in white blood cells |
20 | 1.00– 2.66 |
Olr1687 | Olfactory receptor Olr1687 | + | None | − |
|
Proportion of
CD4+ cells expressing CD45RC |
13 | 36.86– 62.54 |
Ptprc | Receptor-type tyrosine protein phosphatase C |
+ | None | − |
|
Proportion of
CD4+ cells in T cells |
20 | 14.83– 19.43 |
RGD1559903 | Uncharacterized protein | + | None | − |
|
Proportion of
CD8+ cells expressing CD45RC |
13 | 50.49– 55.97 |
Ptprc | Receptor-type tyrosine protein phosphatase C |
+ | None | − |
|
Proportion of
CD8+ cells with high expression of CD25 |
19 | 52.29– 56.8 |
Sipa1l2 | Signal-induced proliferation-associated 1– like protein 2 |
+ | None | − |
| Lowest weight | 3 | 121.45– 126.25 |
Pak7 | Serine/threonine protein kinase PAK 7 | + | None | − |
|
Weight loss
compared to day 0 |
2 | 169.79– 174.4 |
Fam198b | Protein FAM198B | + | None | − |
|
Serum alkaline
phosphatase |
3 | 18.49– 23.11 |
Lrp1b | Low-density lipoprotein–related protein 1B (deleted in tumors) |
+ | None | − |
|
Serum chloride
concentration |
9 | 32.72– 36.5 |
Uggt1 | UDP- glucose:glycoproteinglucosyltransferase 1 |
+ | None | − |
|
Serum
triglycerides |
4 | 74.8– 79.28 |
Dfna5 | Deafness, autosomal dominant 5 | + | None | − |
|
Weight loss
compared to day 0 |
20 | 2.48– 7.07 |
RT1-Da | RT1 class II histocompatibility antigen Da chain |
− | p.Thr182Ala | Surface exposed, disturbed intermolecular interactions |
|
Weight loss
compared to day 0 |
20 | 2.48– 7.07 |
RT1-Da | RT1 class II histocompatibility antigen Da chain |
− | p.Thr182Met | Surface exposed, disturbed intermolecular interactions |
|
Weight loss
compared to day 0 |
20 | 2.48– 7.07 |
RT1-Bb | RT1 class II histocompatibility antigen, B- 1β chain |
− | p.His200Arg | Surface exposed, disturbed intermolecular interactions |
|
Weight loss
compared to day 0 |
20 | 2.48– 7.07 |
RT1-Bb | RT1 class II histocompatibility antigen, B- 1β chain |
− | p.Thr165Met | Surface exposed, disturbed intermolecular interactions |
|
Weight loss
compared to day 0 |
20 | 2.48– 7.07 |
RT1-Bb | RT1 class II histocompatibility antigen, B- 1β chain |
− | p.Gln162Arg | Surface exposed, disturbed intermolecular interactions |
|
Expression on
RT1B on B cells |
17 | 26.63– 27.55 |
Tbc1d7 | TBC1-domain family member 7 | − | p.Ser116Leu | Surface exposed, disturbed intermolecular interactions |
|
Proportion of B cells in white
blood cells |
1 |
182.36–
186.67 |
Itgal | Integrin αL | − | p.Asn890Ser | Abolished glycosylation |
|
Proportion of CD4+ cells with
high expression of CD25 |
10 | 84.27– 87.32 |
Tbx21 | T-box transcription factor TBX21 | − | p.Gly175Arg | Surface exposed, additional interactions with DNA |
| Ratio of T cells to B cells | 1 | 183.58– 187.41 |
Rabep2 | Rab GTPase–binding effector protein 2 |
− | p.Ile336Thr | Partially buried, disturbed oligomerization |
| Ratio of T cells to B cells | 1 | 183.58– 187.41 |
Itgal | Integrin αL | − | p.Leu806Ser | Surface exposed, disturbed intermolecular interactions |
|
Mean corpuscular red blood cell
volume |
19 | 53.11– 55.80 |
Abcb10 | ATP-binding cassette, sub-family B (MDR/TAP), member 10 |
− | p.Thr233Met | Transport channel exposed, altered transport |
| Platelet count | 12 | 1.00–7.47 | Rfc3 | Replication factor C (Activator 1) | − | p.Pro173Ala | Surface exposed, alteration of the α helix |
|
Proportion of monocytes in
white blood cells |
1 | 250.37– 254.00 |
Pdcd11 | Protein RRP5 homolog | − | p.Glu160Gly | Surface exposed |